The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug
approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum …

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in
Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma …

Objective To describe the impact of omalizumab on asthma management in patients treated
as part of normal clinical practice in the UK National Health Service (NHS). Design A non …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Purpose The necessary treatment duration of omalizumab in patients with severe asthma
remains unclear. Currently, common practice is life-long therapy without adjustment of dose …

Novel targets of omalizumab in asthma : Current Opinion in Pulmonary Medicine Novel targets
of omalizumab in asthma : Current Opinion in Pulmonary Medicine Log in or Register Subscribe …

Background: Patients with severe persistent asthma who are inadequately controlled
despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population …

Abstract Background Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody,
has demonstrated efficacy in clinical trials conducted in patients with moderate to severe …

OBJECTIVE: To evaluate the 16-and 52-week effectiveness of add-on omalizumab
treatment under real-life heterogeneity in patients, settings, and physicians in an open-label …

Background Patients with severe asthma are often inadequately controlled on existing anti‐
asthma therapy, constituting an unmet clinical need. Objective This randomized, double …